An artificial intelligence-based model for prediction of clonal hematopoiesis variants in cell-free DNA samples

Circulating tumor DNA is a critical biomarker in cancer diagnostics, but its accurate interpretation requires careful consideration of clonal hematopoiesis (CH), which can contribute to variants in cell-free DNA and potentially obscure true tumor-derived signals. Accurate detection of somatic variants of CH origin in plasma samples remains challenging in the absence of matched white blood cells sequencing. Here we present an open-source machine learning framework (MetaCH) which classifies variants in cfDNA from plasma-only samples as CH or tumor origin, surpassing state-of-the-art classification rates.

Authors

Institutions

Publication Details

Journal
npj Precision Oncology
Published
2025-05-20
DOI
https://doi.org/10.1038/s41698-025-00921-w
Citations
3
Primary Topic
Cancer Genomics and Diagnostics
Type
article
Field-Weighted Citation Impact
2.81

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

An artificial intelligence-based model for prediction of clonal hematopoiesis variants in cell-free DNA samples

Zhongwu Lai, Gerald J. Sun, J. Carl Barrett, Etai Jacob et al.
3 citations
npj Precision Oncology
Cancer Genomics and Diagnostics
2.81
article

An artificial intelligence-based model for prediction of clonal hematopoiesis variants in cell-free DNA samples

Zhongwu Lai, Gerald J. Sun, J. Carl Barrett, Etai Jacob, Marzieh Haghighi, Elizabeth Choe, Aleksandra Markovets, Gustavo Arango-Argoty
article en
3 citations

Abstract

Circulating tumor DNA is a critical biomarker in cancer diagnostics, but its accurate interpretation requires careful consideration of clonal hematopoiesis (CH), which can contribute to variants in cell-free DNA and potentially obscure true tumor-derived signals. Accurate detection of somatic variants of CH origin in plasma samples remains challenging in the absence of matched white blood cells sequencing. Here we present an open-source machine learning framework (MetaCH) which classifies variants in cfDNA from plasma-only samples as CH or tumor origin, surpassing state-of-the-art classification rates.

npj Precision OncologyVol. 9(1)
AstraZeneca (United States) (US)
AstraZeneca
Openalex Percentile: Top 10%
Cancer Genomics and Diagnostics
2.81
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.